Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Genomics|February 10, 2007
Obscurin-like 1, OBSL1, is a novel cytoskeletal protein related to obscurinSarah B Geisler, Dustin Robinson, Maria Hauringa, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|June 17, 2006
Obscurin is required for the lateral alignment of striated myofibrils in zebrafishMaide O Raeker, Fengyun Su, Sarah B Geisler, et al.
FEBS Letters|March 27, 2007
Different obscurin isoforms localize to distinct sites at sarcomeresAmber L Bowman, Aikaterini Kontrogianni-Konstantopoulos, Sara S Hirsch, et al.
Human Molecular Genetics|April 4, 2014
Functional analysis of candidate genes in 2q13 deletion syndrome implicates FBLN7 and TMEM87B deficiency in congenital heart defects and FBLN7 in craniofacial malformationsMark W Russell, Maide O Raeker, Sarah B Geisler, et al.
Molecular Cancer|October 24, 2006
Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parametersLars O Baumbusch, Simen Myhre, Anita Langerød, et al.
Nature Materials|October 10, 2025
Giant photoconductance at infinite-layer nickelate/SrTiO3 interfaces via an optically induced high-mobility electron gasDavid Sanchez-Manzano, G Krieger, A Raji, et al.
Congenital Heart Disease|April 12, 2014
Chromosomal Imbalances in Patients with Congenital Cardiac Defects: A Meta-analysis Reveals Novel Potential Critical Regions Involved in Heart DevelopmentThor Thorsson, William W Russell, Nour El-Kashlan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamideSharon A Glynn, Brenda J Boersma, Tiffany M Howe, et al.
Future Oncology (London, England)|July 29, 2024
The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancerKamilla Fjermeros, Salim Ghannoum, Stephanie B Geisler, et al.
Pageof 2